ES2952050T3 - Composiciones de exosomas y métodos para su preparación y uso para la regulación y el acondicionamiento de la piel y el cabello - Google Patents
Composiciones de exosomas y métodos para su preparación y uso para la regulación y el acondicionamiento de la piel y el cabello Download PDFInfo
- Publication number
- ES2952050T3 ES2952050T3 ES16833569T ES16833569T ES2952050T3 ES 2952050 T3 ES2952050 T3 ES 2952050T3 ES 16833569 T ES16833569 T ES 16833569T ES 16833569 T ES16833569 T ES 16833569T ES 2952050 T3 ES2952050 T3 ES 2952050T3
- Authority
- ES
- Spain
- Prior art keywords
- exosomes
- skin
- heat shock
- composition
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000001808 exosome Anatomy 0.000 title claims abstract description 232
- 239000000203 mixture Substances 0.000 title claims abstract description 63
- 238000000034 method Methods 0.000 title claims abstract description 50
- 238000002360 preparation method Methods 0.000 title abstract description 19
- 230000033228 biological regulation Effects 0.000 title description 4
- 230000003750 conditioning effect Effects 0.000 title description 3
- 230000035939 shock Effects 0.000 claims abstract description 126
- 210000000130 stem cell Anatomy 0.000 claims abstract description 60
- 230000001965 increasing effect Effects 0.000 claims abstract description 47
- 230000003938 response to stress Effects 0.000 claims abstract description 36
- 230000001105 regulatory effect Effects 0.000 claims abstract description 22
- 230000002500 effect on skin Effects 0.000 claims abstract description 12
- 230000037303 wrinkles Effects 0.000 claims abstract description 11
- 231100000241 scar Toxicity 0.000 claims abstract description 7
- 208000032544 Cicatrix Diseases 0.000 claims abstract description 6
- 230000037387 scars Effects 0.000 claims abstract description 6
- 239000011148 porous material Substances 0.000 claims abstract description 4
- 230000036548 skin texture Effects 0.000 claims abstract description 4
- 230000036572 transepidermal water loss Effects 0.000 claims abstract description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 4
- 238000005299 abrasion Methods 0.000 claims abstract description 3
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims description 27
- 239000004017 serum-free culture medium Substances 0.000 claims description 20
- 210000002950 fibroblast Anatomy 0.000 claims description 15
- 238000004519 manufacturing process Methods 0.000 claims description 15
- 238000012258 culturing Methods 0.000 claims description 14
- 230000005855 radiation Effects 0.000 claims description 14
- 230000000699 topical effect Effects 0.000 claims description 14
- 101710163595 Chaperone protein DnaK Proteins 0.000 claims description 12
- 101710178376 Heat shock 70 kDa protein Proteins 0.000 claims description 12
- 101710152018 Heat shock cognate 70 kDa protein Proteins 0.000 claims description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 10
- 102000012422 Collagen Type I Human genes 0.000 claims description 9
- 108010022452 Collagen Type I Proteins 0.000 claims description 9
- 230000002757 inflammatory effect Effects 0.000 claims description 9
- 239000012679 serum free medium Substances 0.000 claims description 9
- 239000002537 cosmetic Substances 0.000 claims description 8
- 239000001963 growth medium Substances 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 8
- 102000004127 Cytokines Human genes 0.000 claims description 6
- 108090000695 Cytokines Proteins 0.000 claims description 6
- 230000014509 gene expression Effects 0.000 claims description 6
- 230000003169 placental effect Effects 0.000 claims description 6
- 230000035755 proliferation Effects 0.000 claims description 6
- 206010040844 Skin exfoliation Diseases 0.000 claims description 5
- 235000011187 glycerol Nutrition 0.000 claims description 4
- 241001465754 Metazoa Species 0.000 claims description 3
- 239000003963 antioxidant agent Substances 0.000 claims description 3
- 230000003078 antioxidant effect Effects 0.000 claims description 3
- -1 vitamin B3 compound Chemical class 0.000 claims description 3
- 239000000080 wetting agent Substances 0.000 claims description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 2
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 claims description 2
- MSCCTZZBYHQMQJ-AZAGJHQNSA-N Tocopheryl nicotinate Chemical compound C([C@@](OC1=C(C)C=2C)(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)CC1=C(C)C=2OC(=O)C1=CC=CN=C1 MSCCTZZBYHQMQJ-AZAGJHQNSA-N 0.000 claims description 2
- 229930003537 Vitamin B3 Natural products 0.000 claims description 2
- 239000006071 cream Substances 0.000 claims description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 2
- 229940008099 dimethicone Drugs 0.000 claims description 2
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 2
- 235000013870 dimethyl polysiloxane Nutrition 0.000 claims description 2
- 239000006260 foam Substances 0.000 claims description 2
- 239000000499 gel Substances 0.000 claims description 2
- 229920002674 hyaluronan Polymers 0.000 claims description 2
- 229960003160 hyaluronic acid Drugs 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000006210 lotion Substances 0.000 claims description 2
- 229960003512 nicotinic acid Drugs 0.000 claims description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinic acid amide Natural products NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 2
- 229940101267 panthenol Drugs 0.000 claims description 2
- 150000002948 pantothenic acids Chemical class 0.000 claims description 2
- 235000020957 pantothenol Nutrition 0.000 claims description 2
- 239000011619 pantothenol Substances 0.000 claims description 2
- 239000006072 paste Substances 0.000 claims description 2
- 235000019271 petrolatum Nutrition 0.000 claims description 2
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 229960001295 tocopherol Drugs 0.000 claims description 2
- 229930003799 tocopherol Natural products 0.000 claims description 2
- 235000010384 tocopherol Nutrition 0.000 claims description 2
- 239000011732 tocopherol Substances 0.000 claims description 2
- 150000003611 tocopherol derivatives Chemical class 0.000 claims description 2
- 229950009883 tocopheryl nicotinate Drugs 0.000 claims description 2
- 239000011708 vitamin B3 Substances 0.000 claims description 2
- 235000019160 vitamin B3 Nutrition 0.000 claims description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 2
- 210000002826 placenta Anatomy 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract description 89
- 230000001976 improved effect Effects 0.000 abstract description 4
- 230000001939 inductive effect Effects 0.000 abstract description 3
- 210000003491 skin Anatomy 0.000 description 60
- 239000002609 medium Substances 0.000 description 27
- 239000003102 growth factor Substances 0.000 description 18
- 210000002379 periodontal ligament Anatomy 0.000 description 12
- 108090001007 Interleukin-8 Proteins 0.000 description 11
- 102000004890 Interleukin-8 Human genes 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 11
- 210000002510 keratinocyte Anatomy 0.000 description 11
- 230000003239 periodontal effect Effects 0.000 description 11
- 238000011282 treatment Methods 0.000 description 11
- 102000004889 Interleukin-6 Human genes 0.000 description 10
- 108090001005 Interleukin-6 Proteins 0.000 description 10
- 239000003636 conditioned culture medium Substances 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 230000008439 repair process Effects 0.000 description 10
- 108010035532 Collagen Proteins 0.000 description 9
- 102000008186 Collagen Human genes 0.000 description 9
- 238000004113 cell culture Methods 0.000 description 9
- 229920001436 collagen Polymers 0.000 description 9
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 8
- 102100040247 Tumor necrosis factor Human genes 0.000 description 8
- 230000003110 anti-inflammatory effect Effects 0.000 description 8
- 238000005119 centrifugation Methods 0.000 description 8
- 230000021995 interleukin-8 production Effects 0.000 description 8
- 238000012546 transfer Methods 0.000 description 8
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 7
- 206010061218 Inflammation Diseases 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- 230000002062 proliferating effect Effects 0.000 description 7
- 230000001681 protective effect Effects 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 239000003981 vehicle Substances 0.000 description 7
- 238000011534 incubation Methods 0.000 description 6
- 210000004872 soft tissue Anatomy 0.000 description 6
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 5
- 241000605862 Porphyromonas gingivalis Species 0.000 description 5
- 239000012298 atmosphere Substances 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 239000006166 lysate Substances 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 230000008929 regeneration Effects 0.000 description 5
- 238000011069 regeneration method Methods 0.000 description 5
- 230000000451 tissue damage Effects 0.000 description 5
- 231100000827 tissue damage Toxicity 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- 230000029663 wound healing Effects 0.000 description 5
- 208000035874 Excoriation Diseases 0.000 description 4
- 102000015696 Interleukins Human genes 0.000 description 4
- 108010063738 Interleukins Proteins 0.000 description 4
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 4
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 210000001185 bone marrow Anatomy 0.000 description 4
- 230000001143 conditioned effect Effects 0.000 description 4
- 238000004108 freeze drying Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000003076 paracrine Effects 0.000 description 4
- 238000002260 proton detected separated local field spectroscopy Methods 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 230000003248 secreting effect Effects 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
- 208000002260 Keloid Diseases 0.000 description 3
- 238000011529 RT qPCR Methods 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 230000003511 endothelial effect Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 210000002744 extracellular matrix Anatomy 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 210000001117 keloid Anatomy 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 201000001245 periodontitis Diseases 0.000 description 3
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000000770 proinflammatory effect Effects 0.000 description 3
- 238000000575 proteomic method Methods 0.000 description 3
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 3
- 230000017423 tissue regeneration Effects 0.000 description 3
- 239000012049 topical pharmaceutical composition Substances 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 101100507655 Canis lupus familiaris HSPA1 gene Proteins 0.000 description 2
- 230000005778 DNA damage Effects 0.000 description 2
- 231100000277 DNA damage Toxicity 0.000 description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
- 108091058560 IL8 Proteins 0.000 description 2
- 206010040829 Skin discolouration Diseases 0.000 description 2
- 101710127774 Stress response protein Proteins 0.000 description 2
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 description 2
- 206010042496 Sunburn Diseases 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000036569 collagen breakdown Effects 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 230000002431 foraging effect Effects 0.000 description 2
- 229960005150 glycerol Drugs 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 230000003960 inflammatory cascade Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 208000028169 periodontal disease Diseases 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 210000001147 pulmonary artery Anatomy 0.000 description 2
- 238000007634 remodeling Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 238000004626 scanning electron microscopy Methods 0.000 description 2
- 230000009759 skin aging Effects 0.000 description 2
- 230000037380 skin damage Effects 0.000 description 2
- 230000037370 skin discoloration Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 210000002536 stromal cell Anatomy 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- 238000010257 thawing Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 1
- VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 description 1
- HLOFWGGVFLUZMZ-UHFFFAOYSA-N 4-hydroxy-4-(6-methoxynaphthalen-2-yl)butan-2-one Chemical compound C1=C(C(O)CC(C)=O)C=CC2=CC(OC)=CC=C21 HLOFWGGVFLUZMZ-UHFFFAOYSA-N 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 108010081589 Becaplermin Proteins 0.000 description 1
- 241000195940 Bryophyta Species 0.000 description 1
- 108010075254 C-Peptide Proteins 0.000 description 1
- 102100025222 CD63 antigen Human genes 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 description 1
- 108050001049 Extracellular proteins Proteins 0.000 description 1
- 206010019345 Heat stroke Diseases 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 101000934368 Homo sapiens CD63 antigen Proteins 0.000 description 1
- 101000617130 Homo sapiens Stromal cell-derived factor 1 Proteins 0.000 description 1
- 101000613251 Homo sapiens Tumor susceptibility gene 101 protein Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 206010023330 Keloid scar Diseases 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 206010051246 Photodermatosis Diseases 0.000 description 1
- 108010050808 Procollagen Proteins 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 101710088580 Stromal cell-derived factor 1 Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 102000002689 Toll-like receptor Human genes 0.000 description 1
- 108020000411 Toll-like receptor Proteins 0.000 description 1
- 102000008228 Toll-like receptor 2 Human genes 0.000 description 1
- 108010060888 Toll-like receptor 2 Proteins 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 102100040879 Tumor susceptibility gene 101 protein Human genes 0.000 description 1
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 1
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 210000004504 adult stem cell Anatomy 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000003181 biological factor Substances 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000002648 chondrogenic effect Effects 0.000 description 1
- 230000037319 collagen production Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- UPUOLJWYFICKJI-UHFFFAOYSA-N cyclobutane;pyrimidine Chemical class C1CCC1.C1=CN=CN=C1 UPUOLJWYFICKJI-UHFFFAOYSA-N 0.000 description 1
- 230000032459 dedifferentiation Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000011331 genomic analysis Methods 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 210000004263 induced pluripotent stem cell Anatomy 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000004579 marble Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012577 media supplement Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 235000011929 mousse Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 230000014306 paracrine signaling Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 230000008845 photoaging Effects 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000031070 response to heat Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 150000004508 retinoic acid derivatives Chemical class 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 210000002955 secretory cell Anatomy 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000009168 stem cell therapy Methods 0.000 description 1
- 238000011476 stem cell transplantation Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000007669 thermal treatment Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000001419 two-dimensional polyacrylamide gel electrophoresis Methods 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/48—Reproductive organs
- A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
- A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/14—Liposomes; Vesicles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
- A61K8/675—Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/678—Tocopherol, i.e. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/007—Preparations for dry skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0605—Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0607—Non-embryonic pluripotent stem cells, e.g. MASC
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0668—Mesenchymal stem cells from other natural sources
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
- C12N2500/92—Medium free of human- or animal-derived components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2523/00—Culture process characterised by temperature
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Developmental Biology & Embryology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Reproductive Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gynecology & Obstetrics (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Birds (AREA)
- Virology (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Marine Sciences & Fisheries (AREA)
- Pregnancy & Childbirth (AREA)
- Gerontology & Geriatric Medicine (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562199696P | 2015-07-31 | 2015-07-31 | |
| PCT/US2016/044458 WO2017023690A1 (en) | 2015-07-31 | 2016-07-28 | Exosome compositions and methods for preparation and use thereof for regulating and conditioning skin and hair |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2952050T3 true ES2952050T3 (es) | 2023-10-26 |
Family
ID=57943605
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES16833569T Active ES2952050T3 (es) | 2015-07-31 | 2016-07-28 | Composiciones de exosomas y métodos para su preparación y uso para la regulación y el acondicionamiento de la piel y el cabello |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20180147420A1 (https=) |
| EP (2) | EP3328403A4 (https=) |
| JP (2) | JP6980955B2 (https=) |
| CA (2) | CA2993224A1 (https=) |
| ES (1) | ES2952050T3 (https=) |
| HR (1) | HRP20230865T1 (https=) |
| HU (1) | HUE063486T2 (https=) |
| PL (1) | PL3328397T3 (https=) |
| RS (1) | RS64469B1 (https=) |
| SM (1) | SMT202300249T1 (https=) |
| WO (2) | WO2017023690A1 (https=) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018039100A2 (en) * | 2016-08-23 | 2018-03-01 | Albert Einstein College Of Medicine, Inc. | Stem cell-produced microvesicles for treating tendon pathologies |
| CN107006452A (zh) * | 2017-04-20 | 2017-08-04 | 深圳市赛欧细胞生物科技有限公司 | 一种人脐带间充质干细胞源外泌体冻干保存方法及其应用 |
| CN107080753A (zh) * | 2017-04-20 | 2017-08-22 | 深圳市赛欧细胞生物科技有限公司 | 一种人脐带间充质干细胞源外泌体的美容制剂 |
| CN107245472B (zh) * | 2017-06-08 | 2021-08-06 | 北京智能宝生物科技有限公司 | 一种人间充质干细胞外泌体冻干粉的制备方法、使用方法 |
| WO2019004757A2 (ko) * | 2017-06-30 | 2019-01-03 | 주식회사 엑소코바이오 | 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 조성물의 가려움증 억제 또는 개선 용도 |
| KR20190003316A (ko) | 2017-06-30 | 2019-01-09 | 주식회사 엑소코바이오 | 지방줄기세포 유래의 엑소좀 및/또는 세포외 소포체를 유효성분으로 포함하는 조성물의 피부염 개선 용도 |
| WO2019004738A2 (ko) * | 2017-06-30 | 2019-01-03 | 주식회사 엑소코바이오 | 지방줄기세포 유래의 엑소좀을 유효성분으로 포함하는 조성물의 피부염 개선 용도 |
| WO2019040790A1 (en) * | 2017-08-23 | 2019-02-28 | Merakris Therapeutics, Llc | COMPOSITIONS CONTAINING AMNIOTIC COMPONENTS AND METHODS FOR THEIR PREPARATION AND USE |
| WO2019051225A1 (en) * | 2017-09-11 | 2019-03-14 | Symbiocelltech, Llc | ADAPTATION OF HOLLOW FIBER CELL CELL TECHNOLOGY FOR THE PREPARATION OF NEO-ISLANDS OR EXOSOMES FROM STEM CELLS |
| CN111527199A (zh) | 2017-11-16 | 2020-08-11 | 得克萨斯大学体系董事会 | 用于制备来源于msc的外泌体的方法 |
| KR20190060646A (ko) | 2017-11-24 | 2019-06-03 | 주식회사 엑소코바이오 | 줄기세포 유래의 엑소좀 및/또는 세포외 소포체를 유효성분으로 포함하는 조성물의 피부장벽 강화 내지 기능 개선 용도 |
| KR102039302B1 (ko) * | 2017-11-24 | 2019-10-31 | 주식회사 엑소코바이오 | 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 조성물의 피부장벽 강화 내지 기능 개선 용도 |
| WO2019103381A1 (ko) * | 2017-11-24 | 2019-05-31 | 주식회사 엑소코바이오 | 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 조성물의 피부장벽 강화 내지 기능 개선 용도 |
| US12036325B2 (en) | 2017-12-14 | 2024-07-16 | Mayo Foundation For Medical Education And Research | Purified exosome products, method of making, and methods of using |
| WO2019139762A1 (en) * | 2018-01-09 | 2019-07-18 | Zen-Bio, Inc. | Exosome compositions and use thereof for joint disorders and diseases |
| EP3775258A4 (en) | 2018-03-28 | 2022-01-26 | Board of Regents, The University of Texas System | IDENTIFICATION OF EPIGENETIC ALTERATIONS IN DNA ISOLATED FROM EXOSOMES |
| CA3099387A1 (en) * | 2018-05-04 | 2019-11-07 | Figene, Llc | Pain-reducing effects of fibroblasts and treatment of pain |
| RU2710368C2 (ru) * | 2018-05-29 | 2019-12-26 | Станислав Евгеньевич Волчков | Способ получения и концентрирования микроРНК-содержащих экзосом мультипотентных мезенхимально-стромальных клеток для применения в косметических и лекарственных средствах для стимуляции регенеративных процессов и замедления процессов старения |
| EP3801028A4 (en) | 2018-05-30 | 2022-04-13 | Direct Biologics LLC | A growth factor and extracellular vesicle frozen or powdered additive comprising a mesenchymal stem cell (msc) preparation and methods of use |
| KR102646145B1 (ko) * | 2018-05-31 | 2024-03-11 | 주식회사 엑소코바이오 | 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 모공 축소용 조성물 |
| WO2019231133A1 (ko) * | 2018-05-31 | 2019-12-05 | 주식회사 엑소코바이오 | 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 모공 축소용 조성물 |
| CN108715834B (zh) * | 2018-06-01 | 2021-09-14 | 天晴干细胞股份有限公司 | 一种富含cd41+、cd81+微囊的血小板裂解液制备方法 |
| KR102176845B1 (ko) * | 2018-10-02 | 2020-11-10 | 주식회사 스템온 | 유도된 엑소좀을 포함하는 피부 재생 및 상처 치유용 조성물 |
| CA3286605A1 (en) | 2018-11-04 | 2025-11-29 | Fibrobiologics, Inc. | Treatment of cachexia using fibroblast cells and products thereof |
| US12569517B2 (en) | 2019-02-07 | 2026-03-10 | Direct Biologics, Llc | Method for treating osteoarthritis with mesenchymal stem cell exosomes |
| KR20220012220A (ko) | 2019-02-28 | 2022-02-03 | 메라크리스 테라퓨틱스 엘엘씨 | 양수 유래 세포외 소포체 및 상처 치유를 위한 이의 용도 |
| WO2020180311A1 (en) * | 2019-03-06 | 2020-09-10 | Zen-Bio, Inc. | Plant-based exosome compositions and use thereof for rejuvenating skin |
| US20220202871A1 (en) * | 2019-04-29 | 2022-06-30 | Direct Biologics, Llc | Method for the treatment of periodontal disease using characterized mesenchymal stem cell growth factors and exosomes |
| US12213995B2 (en) | 2019-07-18 | 2025-02-04 | Direct Biologics, Llc | Preparations comprising mesenchymal stem cells and cannabinoids and methods of their use |
| JP2021040551A (ja) * | 2019-09-11 | 2021-03-18 | 富士フイルム株式会社 | 培地組成物、キット、間葉系幹細胞組成物の製造方法、間葉系幹細胞組成物、間葉系幹細胞、細胞培養上清および細胞外小胞 |
| CN110559254A (zh) * | 2019-10-20 | 2019-12-13 | 张新梅 | 一种外泌体组合物、其制备方法及应用 |
| MX2022005107A (es) * | 2019-11-04 | 2023-01-11 | Omar Mohamed Salah Eldin Ahmed Eltookhy | Metodo de recubrimiento y secado de vesiculas extracelulares derivadas de celulas madre heterogeneas. |
| CN110721198A (zh) * | 2019-11-08 | 2020-01-24 | 赵凯 | 一种预防癫痫产生脑损伤的外泌体喷雾的制作工艺 |
| US20230051925A1 (en) * | 2020-01-20 | 2023-02-16 | Ev Cell Biotech (Guangzhou) Co., Ltd. | Vesicle and use thereof |
| WO2021147922A1 (zh) * | 2020-01-20 | 2021-07-29 | 医微细胞生物技术(广州)有限公司 | 细胞外囊泡及其在皮肤产品的用途 |
| US12077780B2 (en) | 2020-02-14 | 2024-09-03 | Allergan Sales, Llc | Conditioned medium from cells cultured under hypoxic conditions and uses thereof |
| KR20230004709A (ko) | 2020-04-22 | 2023-01-06 | 다이렉트 바이오로직스 엘엘씨 | 감염성 질환과 연관된 염증성 병태를 치료하기 위한 방법 및 조성물 |
| US20240390551A1 (en) * | 2021-01-20 | 2024-11-28 | Research & Business Foundation Sungkyunkwan University | Filler composition for reducing skin wrinkles comprising stem cell-derived exosomes, hyaluronic acid, and bdde and method for preparing same |
| KR102368442B1 (ko) * | 2021-02-19 | 2022-02-28 | 주식회사 엑소코바이오 | 생리활성이 강화된 엑소좀의 생산방법 및 이의 응용 |
| TW202235614A (zh) * | 2021-03-11 | 2022-09-16 | 長新生醫國際股份有限公司 | 幹細胞凍乾粉之製造方法 |
| CN113041259B (zh) * | 2021-03-23 | 2023-05-12 | 哈尔滨科技实业开发有限公司 | 牙髓干细胞外泌体制剂及制备方法和应用 |
| JP2024512764A (ja) * | 2021-03-31 | 2024-03-19 | ニュートラシューティカル ウェルネス インコーポレイテッド | 植物由来エキソソーム様ナノベシクル又はエキソソームを含む組成物及びその使用方法 |
| CN113384518A (zh) * | 2021-07-27 | 2021-09-14 | 山西遗传资源细胞库有限公司 | 一种干细胞外泌体应用于面膜的方法 |
| JPWO2023079655A1 (https=) * | 2021-11-04 | 2023-05-11 | ||
| CN113940912B (zh) * | 2021-12-09 | 2024-04-16 | 深圳市泓浩生物科技有限公司 | 抗衰老的组合物及其应用 |
| CN116099056A (zh) * | 2023-04-07 | 2023-05-12 | 云南云科特色植物提取实验室有限公司 | 一种含仿生纹理结构的人工皮肤及其制备方法 |
| CN116790482A (zh) * | 2023-06-12 | 2023-09-22 | 成都诺医德医学检验实验室有限公司 | 一种刺激皮肤类器官分泌外泌体的方法 |
| US20250041348A1 (en) * | 2023-08-03 | 2025-02-06 | Wisconsin Alumni Research Foundation | Extracellular vesicle therapy to treat orthopedic injury |
| US12502407B2 (en) | 2024-04-25 | 2025-12-23 | Direct Biologics, Llc | Treatment of fistula with bone marrow mesenchymal stem cell derived extracellular vesicles |
| CN118576721A (zh) * | 2024-05-27 | 2024-09-03 | 深圳市中安康华生物科技有限公司 | 一种外泌体复合生物制剂及其制备方法与应用 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5348945A (en) * | 1990-04-06 | 1994-09-20 | Wake Forest University | Method of treatment with hsp70 |
| US5593682A (en) * | 1995-12-29 | 1997-01-14 | Eastman Chemical Company | Skin treating composition |
| AT409379B (de) * | 1999-06-02 | 2002-07-25 | Baxter Ag | Medium zur protein- und serumfreien kultivierung von zellen |
| JP2004331602A (ja) * | 2003-05-09 | 2004-11-25 | Arysta Lifescience Corp | 皮膚外用剤 |
| EP1514539A3 (en) * | 2003-05-14 | 2005-05-04 | Signal Investment & Management Co. | Micro-encapsulated topical analgesic for pain relief and sleeve comprising it |
| US20060143782A1 (en) * | 2004-10-07 | 2006-07-06 | Sherry Ajluni | Glove with skin lotion |
| US8022037B2 (en) * | 2007-01-08 | 2011-09-20 | University Of Southern California | Skin wound healing compositions and methods of use thereof |
| EP2254586B1 (en) * | 2008-02-22 | 2015-04-08 | Agency For Science, Technology And Research (A*star) | Mesenchymal stem cell particles |
| EP2620156B1 (en) * | 2010-08-23 | 2019-03-27 | Kang Stem Biotech Co., Ltd. | Pharmaceutical composition for preventing or treating immune diseases or inflammatory diseases, containing stem cells treated with nod2 agonist or cultured product thereof |
| EP2629782B1 (en) * | 2010-10-18 | 2019-02-20 | Agency For Science, Technology And Research | Use of exosomes derived from mesenchymal stem cells to promote or enhance hair growth |
| US9119974B2 (en) * | 2011-03-04 | 2015-09-01 | Ahmed H. Al-Qahtani | Skin cream |
| US9901600B2 (en) * | 2011-03-11 | 2018-02-27 | Children's Medical Center Corporation | Methods and compositions relating to mesenchymal stem cell exosomes |
| JP3171007U (ja) * | 2011-06-28 | 2011-10-13 | ヘルスアシスト株式会社 | 腕肩美容パックシート |
| US9427450B2 (en) * | 2012-01-31 | 2016-08-30 | Xon Cells, Inc. | Therapeutic immune modulation by stem cell secreted exosomes |
| EP2687219A1 (en) * | 2012-07-18 | 2014-01-22 | Universität Duisburg-Essen | Use of preparations comprising exosomes derived from mesenchymal stem cells (MSCs) in the prevention and therapy of inflammatory conditions |
| WO2014159662A1 (en) * | 2013-03-13 | 2014-10-02 | University Of Miami | Method for isolation and purification of microvesicles from cell culture supernatants and biological fluids |
| US20160120805A1 (en) * | 2013-06-05 | 2016-05-05 | The Trustees Of Columbia University In The City Of New York | Exosomes for orofacial diagnostics and therapeutics |
| JP2015101541A (ja) * | 2013-11-21 | 2015-06-04 | ポーラ化成工業株式会社 | 皮膚関連酵素活性化剤 |
| JP6253361B2 (ja) * | 2013-11-21 | 2017-12-27 | ポーラ化成工業株式会社 | 皮膚外用剤 |
| US9464272B2 (en) * | 2013-12-12 | 2016-10-11 | Stemnion, Inc. | Cell-derived composition |
| CN104488850B (zh) * | 2014-11-28 | 2016-11-02 | 广州赛莱拉干细胞科技股份有限公司 | 一种制备人羊膜间充质干细胞外泌体冻干粉的方法 |
-
2016
- 2016-07-28 HR HRP20230865TT patent/HRP20230865T1/hr unknown
- 2016-07-28 WO PCT/US2016/044458 patent/WO2017023690A1/en not_active Ceased
- 2016-07-28 RS RS20230599A patent/RS64469B1/sr unknown
- 2016-07-28 JP JP2018525514A patent/JP6980955B2/ja active Active
- 2016-07-28 SM SM20230249T patent/SMT202300249T1/it unknown
- 2016-07-28 ES ES16833569T patent/ES2952050T3/es active Active
- 2016-07-28 WO PCT/US2016/044453 patent/WO2017023689A1/en not_active Ceased
- 2016-07-28 CA CA2993224A patent/CA2993224A1/en not_active Abandoned
- 2016-07-28 JP JP2018525513A patent/JP6719559B2/ja active Active
- 2016-07-28 HU HUE16833569A patent/HUE063486T2/hu unknown
- 2016-07-28 CA CA2993227A patent/CA2993227C/en active Active
- 2016-07-28 EP EP16833568.5A patent/EP3328403A4/en not_active Withdrawn
- 2016-07-28 EP EP16833569.3A patent/EP3328397B1/en active Active
- 2016-07-28 PL PL16833569.3T patent/PL3328397T3/pl unknown
-
2018
- 2018-01-31 US US15/884,545 patent/US20180147420A1/en not_active Abandoned
- 2018-01-31 US US15/884,921 patent/US20180177828A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP3328397B1 (en) | 2023-07-12 |
| US20180147420A1 (en) | 2018-05-31 |
| PL3328397T3 (pl) | 2023-10-16 |
| WO2017023690A1 (en) | 2017-02-09 |
| EP3328403A1 (en) | 2018-06-06 |
| RS64469B1 (sr) | 2023-09-29 |
| EP3328397A1 (en) | 2018-06-06 |
| EP3328397A4 (en) | 2019-04-03 |
| HUE063486T2 (hu) | 2024-01-28 |
| CA2993224A1 (en) | 2017-02-09 |
| JP6719559B2 (ja) | 2020-07-08 |
| JP2018522593A (ja) | 2018-08-16 |
| US20180177828A1 (en) | 2018-06-28 |
| EP3328403A4 (en) | 2019-04-17 |
| WO2017023689A1 (en) | 2017-02-09 |
| CA2993227C (en) | 2020-07-21 |
| EP3328397C0 (en) | 2023-07-12 |
| JP6980955B2 (ja) | 2021-12-15 |
| HRP20230865T1 (hr) | 2023-11-10 |
| CA2993227A1 (en) | 2017-02-09 |
| SMT202300249T1 (it) | 2023-09-06 |
| JP2018522071A (ja) | 2018-08-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2952050T3 (es) | Composiciones de exosomas y métodos para su preparación y uso para la regulación y el acondicionamiento de la piel y el cabello | |
| Damayanti et al. | Mesenchymal stem cell secretome for dermatology application: a review | |
| US20190160104A1 (en) | Platelet lysate gel | |
| Kim et al. | Enhanced wound healing effect of canine adipose-derived mesenchymal stem cells with low-level laser therapy in athymic mice | |
| US10639264B2 (en) | Mesenchymal stem cell extract and its use | |
| CN108699519A (zh) | 干细胞衍生的含有大量生长因子的外来体 | |
| US20070154529A1 (en) | Uses of dna binding proteins | |
| JP2022020814A (ja) | 幹細胞性維持及び賦活化剤、並びにそれを含有する皮膚外用剤及び化粧品 | |
| Ahmad et al. | Mechanistic insights into dental stem cells‐derived exosomes in regenerative endodontics | |
| Kee et al. | Umbilical cord mesenchymal stromal cell-derived small extracellular vesicles modulate skin matrix synthesis and pigmentation | |
| Jiang et al. | The role and mechanism of engineered nanovesicles derived from hair follicle mesenchymal stem cells in the treatment of UVB‐induced skin photoaging | |
| CN102781455B (zh) | 来自来源于正在生长的鹿茸的干细胞的细胞匀浆物、获得其的方法及其用途 | |
| KR20250037691A (ko) | 중간엽 줄기세포 스페로이드, 이의 제조방법 및 이를 포함하는 조성물 | |
| KR102153636B1 (ko) | 줄기세포 배양용 무혈청 배지 조성물 및 줄기세포의 배양방법 | |
| KR102191789B1 (ko) | 저분자 화합물로 인한 인간 골수유래 중간엽 줄기세포 성장인자의 발현 제어 및 분비를 촉진하는 성장인자 대량 생산방법 | |
| Aberdam et al. | Extracellular vesicles including exosomes for hair follicle regeneration | |
| Maguire et al. | Stem Cell Secretome for Skincare: Of Cell Types, Exosomes, Extracellular Vesicles, and Soluble Fractions | |
| KR102153637B1 (ko) | 줄기세포 배양용 무혈청 배지 조성물 및 줄기세포의 배양방법 | |
| KR102153635B1 (ko) | 줄기세포 배양용 무혈청 배지 조성물 및 줄기세포의 배양방법 | |
| JP2025538460A (ja) | 毛髪の成長および再生を誘導、刺激、および促進するための、臍帯の間葉系幹細胞の培養に由来する馴化培地の使用 | |
| Gurney¹ et al. | extracellular vesicles containing cargo that specifically enhances | |
| Taub a–c | Cosmeceuticals Using Growth Factors and Stem Cells | |
| Gomiero | Novel regenerative medicine approaches with the use of adult mesenchymal stem cells: in vitro and in vivo experimental procedures | |
| Hirt-Burri et al. | Biologicals and fetal cell therapy for wound healing and scar management | |
| 김효주 | Enhanced Wound Healing Effect of Canine Adipose-Derived Mesenchymal Stem Cells with Low-Level Laser Therapy in Athymic Mice |